ARCHIVES

5-Day Strut-based Brachytherapy Produced Low Recurrence Rates

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

ImClone Offered C225 Deal To Seven Firms Prior To BMS

February 22, 2002

Draft of National Action Plan On Breast Cancer Targets Health Care, Research, Policy

March 23, 1994

Fox Chase-U.Pa. Radiation Dept. Received Contract

October 12, 1979

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

March 31, 2000

In Brief: Three NCI Basic Science Centers Rank In Index Of Citations; Novello: Help More Smokers Quit

August 2, 1991